AR-V7 and prostate cancer: The watershed for treatment selection?

被引：49

作者：

Ciccarese, Chiara ^{[1
]}

Santoni, Matteo ^{[2
]}

Brunelli, Matteo ^{[3
]}

Buti, Sebastiano ^{[4
]}

Modena, Alessandra ^{[1
]}

Nabissi, Massimo ^{[5
]}

Artibani, Walter ^{[6
]}

Martignoni, Guido ^{[3
]}

Montironi, Rodolfo ^{[7
]}

Tortora, Giampaolo ^{[1
]}

Massari, Francesco ^{[1
]}

机构：

[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Ple LA Scuro 10, I-37100 Verona, Italy

[2] Univ Marche Reg, Med Oncol, AOU Osped Riuniti, Polytech, Ancona, Italy

[3] Univ Verona, AOUI, Dept Pathol & Diagnost, I-37100 Verona, Italy

[4] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[5] Univ Camerino, Sch Pharm, Expt Med Sect, I-62032 Camerino, Italy

[6] Univ Verona, Azienda Osped Univ Integrata, Urol Clin, Dept Oncol & Surg Sci, I-37100 Verona, Italy

[7] Polytech Univ Marche Reg, Sch Med, AOU Osped Riuniti, Sect Pathol Anat, Ancona, Italy

来源：

CANCER TREATMENT REVIEWS | 2016年 / 43卷

关键词：

Prostate cancer; Androgen receptor; Splice variant; AR-V7; Prognostic role; Anti-androgens sensitivity; Taxane sensitivity; ANDROGEN RECEPTOR-ACTIVITY; SPLICE VARIANTS; DNA-BINDING; INCREASED SURVIVAL; STEROID-BINDING; SMALL-MOLECULE; HINGE REGION; TARGET GENES; RESISTANT; ENZALUTAMIDE;

D O I：

10.1016/j.ctrv.2015.12.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The androgen receptor (AR) plays a key role in progression to metastatic castration-resistant prostate cancer (mCRPC). Despite the recent progress in targeting persistent AR activity with the next generation hormonal therapies (abiraterone acetate and enzalutamide), resistance to these agents limits therapeutic efficacy for many patients. Several explanations for response and/or resistance to abiraterone acetate and enzalutamide are emerging, but growing interest is focusing on importance of AR splice variants (AR-Vs) and in particular of AR-V7. Increasing evidences highlight the concept that variant expression could be used as a potential predictive biomarker and a therapeutic target in advanced prostate cancer. Therefore, understanding the mechanisms of treatment resistance or sensitivity can help to achieve a more effective management of mCRPC, increasing clinical outcomes and representing a promising and engaging area of prostate cancer research. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：27 / 35

页数：9

共 87 条

[61] Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer [J].

Qu, Yuanyuan ;

Dai, Bo ;

Ye, Dingwei ;

Kong, Yunyi ;

Chang, Kun ;

Jia, Zhongwei ;

Yang, Xiaoqun ;

Zhang, Hailiang ;

Zhu, Yao ;

Shi, Guohai .

SCIENTIFIC REPORTS, 2015, 5

[62] Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer [J].

Rathkopf, Dana E. ;

Morris, Michael J. ;

Fox, Josef J. ;

Danila, Daniel C. ;

Slovin, Susan F. ;

Hager, Jeffrey H. ;

Rix, Peter J. ;

Maneval, Edna Chow ;

Chen, Isan ;

Goenen, Mithat ;

Fleisher, Martin ;

Larson, Steven M. ;

Sawyers, Charles L. ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (28) :3525-+

[63] Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy [J].

Ryan, Charles J. ;

Smith, Matthew R. ;

de Bono, Johann S. ;

Molina, Arturo ;

Logothetis, Christopher J. ;

de Souza, Paul ;

Fizazi, Karim ;

Mainwaring, Paul ;

Piulats, Josep M. ;

Ng, Siobhan ;

Carles, Joan ;

Mulders, Peter F. A. ;

Basch, Ethan ;

Small, Eric J. ;

Saad, Fred ;

Schrijvers, Dirk ;

Van Poppel, Hendrik ;

Mukherjee, Som D. ;

Suttmann, Henrik ;

Gerritsen, Winald R. ;

Flaig, Thomas W. ;

George, Daniel J. ;

Yu, Evan Y. ;

Efstathiou, Eleni ;

Pantuck, Allan ;

Winquist, Eric ;

Higano, Celestia S. ;

Taplin, Mary-Ellen ;

Park, Youn ;

Kheoh, Thian ;

Griffin, Thomas ;

Scher, Howard I. ;

Rathkopf, Dana E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (02) :138-148

[64] Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy [J].

Scher, Howard I. ;

Fizazi, Karim ;

Saad, Fred ;

Taplin, Mary-Ellen ;

Sternberg, Cora N. ;

Miller, Kurt ;

de Wit, Ronald ;

Mulders, Peter ;

Chi, Kim N. ;

Shore, Neal D. ;

Armstrong, Andrew J. ;

Flaig, Thomas W. ;

Flechon, Aude ;

Mainwaring, Paul ;

Fleming, Mark ;

Hainsworth, John D. ;

Hirmand, Mohammad ;

Selby, Bryan ;

Seely, Lynn ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (13) :1187-1197

[65] Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains [J].

Schoenmakers, E ;

Alen, P ;

Verrijdt, G ;

Peeters, B ;

Verhoeven, G ;

Rombauts, W ;

Claessens, F .

BIOCHEMICAL JOURNAL, 1999, 341 :515-521

[66] The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer [J].

Schweizer, Michael T. ;

Zhou, Xian C. ;

Wang, Hao ;

Bassi, Sunakshi ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Antonarakis, Emmanuel S. .

EUROPEAN UROLOGY, 2014, 66 (04) :646-652

[67] Formation of the androgen receptor transcription complex [J].

Shang, YF ;

Myers, M ;

Brown, M .

MOLECULAR CELL, 2002, 9 (03) :601-610

[68]

Steinestel J, 2015, ONCOTARGET

[69] Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors [J].

Sun, Feng ;

Chen, He-ge ;

Li, Wei ;

Yang, Xi ;

Wang, Xin ;

Jiang, Richeng ;

Guo, Zhiyong ;

Chen, Hegang ;

Huang, Jiaoti ;

Borowsky, Alexander D. ;

Qiu, Yun .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (03) :1529-1539

[70] Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant [J].

Sun, Shihua ;

Sprenger, Cynthia C. T. ;

Vessella, Robert L. ;

Haugk, Kathleen ;

Soriano, Kathryn ;

Mostaghel, Elahe A. ;

Page, Stephanie T. ;

Coleman, Ilsa M. ;

Nguyen, Holly M. ;

Sun, Huiying ;

Nelson, Peter S. ;

Plymate, Stephen R. .

JOURNAL OF CLINICAL INVESTIGATION, 2010, 120 (08) :2715-2730

← 1 2 3 4 5 6 7 8 9 →